- The 8 States Most Likely to Legalize Marijuana Next
- Behind Russia's Current Crisis: It's Not the Ruble, It's Putin
- Would you invest in the U.S. Postal Service?
- Why Jim Cramer Says it Could be Too Late to Enter the Stock Market Rally Now
- Apple (AAPL) Stock Declining Today Amid Allegations of Poor Working Conditions in China
Investors looking for growth prescription and potential 20% gains in the next 12 months should consider this company.
TheStreet's Jim Cramer says Rite Aid is not done going higher.
Stocks climbed higher in midday trading Thursday, a day after the Federal Reserve said it can be 'patient' about when it will make the first rate hike.
Christmas came early for drugstore chain Rite Aid. The company reported third-quarter results that topped Wall Street estimates.
Congrats to David Schenkein of Agios and Nick Leschly of Bluebird Bio for snagging 'Best' honors, while the ignominious (dis)honor of 'Worst' goes to Martin Shkreli, formerly of Retrophin.
Gilead, Sangamo and Bluebird were great calls, Alexion and Vertex not so much.
For Thursday, Dec 18th 2014, we keep an eye on three notable earnings including drugstore chain Rite Aid (RAD), consulting firm Accenture (ACN), and athletic apparel company Nike (NKE).
To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.
Auspex is expected to seek U.S. approval for SD-809 next year.
Express Scripts Holding Company is looking for another chief financial officer less than a year after Cathy R. Smith joined the pharmacy benefits manager from retail giant Walmart.
Reams of stocks make sense on a pullback. And what looks bad? Anything even remotely connected to oil and gas.
Wall Street analysts are making their bets on which stocks will be the best to own in 2015.
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
By Marguerite Arnold
Native Americans will soon be able to move from the casino business to the pot business to boost tribal income.
InspireMD sales will gain traction in 2015 due to the latest version of its drug coated stent as well as the company's return to European markets.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV